Associations - AKT1 mutation

BIOMARKER:

AKT1 mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

AKT1 mutation AKT1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: B - Late Trials GDC-0068 Sensitive : B
AKT1 mutation AKT1 mutation	Colorectal Cancer CRC	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
AKT1 mutation AKT1 mutation	Breast Cancer Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
AKT1 mutation AKT1 mutation	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
AKT1 mutation AKT1 mutation	Prostate Cancer Prostate Cancer	enzalutamide + AZD5363 Sensitive: D – Preclinical enzalutamide + AZD5363 Sensitive : D